Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab and high-dose trastuzumab in HER2+ MBC with CNS metastases
NCT02536339Phase 2Completed
- Sponsor
- Genentech
- Start
- Dec 2015
- Primary completion
- May 2019
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab in breast cancer, brain metastasis (BM), sponsored by Genentech. Started Dec 2015; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancerbrain metastasis (BM)
Beyond the preview
Go deeper on NCT02536339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02536339.